The FDA has approved a new Vertex Pharmaceuticals cystic fibrosis drug, clearing the way for the Boston company to bring to the market its third treatment for the inherited disorder.
The new Vertex (NASDAQ: VRTX) drug pairs the already approved ivacaftor (Kalydeco) with the newly approved drug tezacaftor. Vertex set a list price for its ivacaftor/tezacaftor (Symdeko) combination at $292,000 per year.
Cystic fibrosis (CF) is a genetic disorder that causes a thick buildup of mucus in the lungs and pancreas. The approval of ivacaftor/tezacaftor strengthens Vertex’s case that drug combinations are the right approach to treating the disease. The… Read more »
UNDERWRITERS AND PARTNERS